Jump to main content

First Gene Therapy for Hemophilia B, CSL Behring’s HEMGENIX®, Approved by the European Commission

Approval of HEMGENIX® underscores CSL Behring’s promise to deliver life-changing innovations that have the potential to help patients lead full lives


Global biotechnology leader CSL Behring today announced that the European Commission has granted conditional marketing authorization (CMA) for HEMGENIX® (etranacogene dezaparvovec).